Thurston Springer Miller Herd & Titak Inc. Has $14.22 Million Holdings in Eli Lilly and Company (NYSE:LLY)

Thurston Springer Miller Herd & Titak Inc. boosted its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 31.5% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 17,209 shares of the company's stock after acquiring an additional 4,124 shares during the quarter. Eli Lilly and Company makes up approximately 2.4% of Thurston Springer Miller Herd & Titak Inc.'s holdings, making the stock its 5th biggest holding. Thurston Springer Miller Herd & Titak Inc.'s holdings in Eli Lilly and Company were worth $14,216,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Elevate Capital Advisors LLC bought a new position in shares of Eli Lilly and Company in the 4th quarter valued at about $262,000. Capital & Planning LLC boosted its stake in shares of Eli Lilly and Company by 15.6% in the 4th quarter. Capital & Planning LLC now owns 481 shares of the company's stock valued at $371,000 after purchasing an additional 65 shares during the last quarter. Garner Asset Management Corp boosted its stake in shares of Eli Lilly and Company by 2.3% in the 4th quarter. Garner Asset Management Corp now owns 532 shares of the company's stock valued at $411,000 after purchasing an additional 12 shares during the last quarter. Brighton Jones LLC boosted its stake in shares of Eli Lilly and Company by 22.0% in the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company's stock valued at $7,409,000 after purchasing an additional 1,730 shares during the last quarter. Finally, Union Bancaire Privee UBP SA bought a new position in shares of Eli Lilly and Company in the 4th quarter valued at about $49,534,000. Institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Stock Down 0.1%

LLY stock traded down $0.71 during mid-day trading on Thursday, hitting $765.13. 3,632,853 shares of the company were exchanged, compared to its average volume of 3,650,450. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. The firm has a market cap of $725.14 billion, a P/E ratio of 65.34, a P/E/G ratio of 1.40 and a beta of 0.48. The firm's 50 day simple moving average is $772.75 and its 200 day simple moving average is $799.41. Eli Lilly and Company has a 1-year low of $677.09 and a 1-year high of $972.53.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its earnings results on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing the consensus estimate of $4.64 by ($1.30). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. The company had revenue of $12.73 billion for the quarter, compared to analyst estimates of $12.77 billion. During the same quarter last year, the business posted $2.58 earnings per share. The business's quarterly revenue was up 45.2% on a year-over-year basis. On average, sell-side analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Friday, May 16th will be issued a dividend of $1.50 per share. The ex-dividend date of this dividend is Friday, May 16th. This represents a $6.00 dividend on an annualized basis and a yield of 0.78%. Eli Lilly and Company's payout ratio is 48.82%.

Insider Buying and Selling

In related news, CAO Donald A. Zakrowski sold 1,000 shares of the business's stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total transaction of $818,240.00. Following the transaction, the chief accounting officer now directly owns 5,840 shares in the company, valued at approximately $4,778,521.60. The trade was a 14.62% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.13% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on LLY shares. The Goldman Sachs Group raised shares of Eli Lilly and Company from a "neutral" rating to a "buy" rating and reduced their price objective for the stock from $892.00 to $888.00 in a research note on Tuesday, April 8th. Cantor Fitzgerald started coverage on shares of Eli Lilly and Company in a research note on Tuesday, April 22nd. They set an "overweight" rating and a $975.00 price objective on the stock. HSBC lowered shares of Eli Lilly and Company from a "buy" rating to a "reduce" rating and reduced their price objective for the stock from $1,150.00 to $700.00 in a research note on Monday, April 28th. UBS Group reduced their price objective on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating on the stock in a research note on Friday, May 2nd. Finally, Hsbc Global Res lowered shares of Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a research note on Monday, April 28th. One research analyst has rated the stock with a sell rating, three have given a hold rating and eighteen have assigned a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $1,011.37.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.